Background High-dose therapy with supporting autologous stem-cell transplantation remains
a controversial treatment for cancer. In multiple myeloma, first-line regimens incorporating …

The antiangiogenic activity of thalidomide (Thal), coupled with an increase in bone marrow
angiogenesis in multiple myeloma (MM), provided the rationale for the use of Thal in MM. …

Based on the clinical features of myeloma and related malignancies of plasma cells, it has
been possible to generate a model system of myeloma progression from a normal plasma cell …

Background Bisphosphonates reduce the risk of skeletal events in patients with malignant
bone disease, and zoledronic acid has shown potential anticancer effects in preclinical and …

Purpose At the molecular level, myeloma is characterized by copy number abnormalities and
recurrent translocations into the immunoglobulin heavy chain locus. Novel methods, such …

A novel nonmyeloablative conditioning regimen was investigated in 44 patients with
hematologic malignancies. The median patient age was 41 years. Many of the patients had high-…

… N Engl J Med 335:91-97, 1996 6. Child JA, … Paiva B, Vidriales MB, Cerveró J, et al: Multiparameter
flow cytometric remission is the most relevant prognostic factor for multiple myeloma …

Thalidomide maintenance has the potential to modulate residual multiple myeloma (MM)
after an initial response. This trial compared the effect of thalidomide maintenance and no …

To obtain a comprehensive genomic profile of presenting multiple myeloma cases we
performed high-resolution single nucleotide polymorphism mapping array analysis in 114 …

The association of genetic lesions detected by fluorescence in situ hybridization (FISH) with
survival was analyzed in 1069 patients with newly presenting myeloma treated in the …